Does Skipping This Skincare Step Make Sunscreen Less Effective? Dermatologists Weigh In originally appeared on Parade.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

In this video, Raj Chovatiya, MD, PhD, discusses the latest findings on the use of topical roflumilast in patients with ...

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.